ClinicalTrialsFinder

Resectable NSCLC Clinical Trials in Yangzhou, Jiangsu

1 recruitingYangzhou, Jiangsu, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC

Resectable NSCLC
Northern Jiangsu People's Hospital20 enrolled1 locationNCT07050056